# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Lake Street analyst Frank Takkinen downgrades Silk Road Medical (NASDAQ:SILK) from Buy to Hold and lowers the price target f...
- SEC Filing
Boston Scientific to acquire Silk Road Medical for $1.26 billion, enhancing its vascular portfolio with Silk Road's TCAR sy...